Tuesday, December 01, 2020 2:13:54 PM
A Different View on LEAPS/Covid
Everyone here seems pretty pessimistic about the LEAPS treatment results that were released today. But I think differently than most of you about this. Yes they did see how effective it was as a vaccine, who cares. BUT they also looked at it as a therapeutic treatment.
For those of you who don't know what that is, here is the defintion:
Therapeutic treatment is designed to treat an illness or to improve a person's health, rather than to prevent an illness.
They injected mice with LETHAL doses of COVID and in the treatment group, 40% survived. That's pretty huge imo. For two reasons.
1. There isn't a current therapeutic treatment that works well in helping people recover from COVID who already have it. Remdesivir was supposedly one of the big ones, which has since shown it doesn't really help patients recover from COVID.
2. They gave these mice LETHAL doses. And it saved 40% of them. No current treatment offers anything like that. On top of that I wonder how effective it is treating/improving COVID symptoms in more minor cases or at the beginning of the disease?
Bonus 3rd reason: COVID will always need a viable treatment option for patients going forward for years and years to come. Hospitals will want options to give to patients to help them get out of the hospitals quickly. There is still time and need for more therapeutic medicines. This is by no means a nothing burger.
TLDR: There is a lot of potential here for treating patients already infected with COVID. If they can get some more funding this could be accelerated quickly.
Everyone here seems pretty pessimistic about the LEAPS treatment results that were released today. But I think differently than most of you about this. Yes they did see how effective it was as a vaccine, who cares. BUT they also looked at it as a therapeutic treatment.
For those of you who don't know what that is, here is the defintion:
Therapeutic treatment is designed to treat an illness or to improve a person's health, rather than to prevent an illness.
They injected mice with LETHAL doses of COVID and in the treatment group, 40% survived. That's pretty huge imo. For two reasons.
1. There isn't a current therapeutic treatment that works well in helping people recover from COVID who already have it. Remdesivir was supposedly one of the big ones, which has since shown it doesn't really help patients recover from COVID.
2. They gave these mice LETHAL doses. And it saved 40% of them. No current treatment offers anything like that. On top of that I wonder how effective it is treating/improving COVID symptoms in more minor cases or at the beginning of the disease?
Bonus 3rd reason: COVID will always need a viable treatment option for patients going forward for years and years to come. Hospitals will want options to give to patients to help them get out of the hospitals quickly. There is still time and need for more therapeutic medicines. This is by no means a nothing burger.
TLDR: There is a lot of potential here for treating patients already infected with COVID. If they can get some more funding this could be accelerated quickly.
Recent CVM News
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/27/2026 09:00:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 12:03:20 PM
- CEL-SCI Reports Fiscal Second Quarter 2026 Results • Business Wire • 05/18/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:00:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:44:06 PM
- CEL-SCI Announces Closing of Public Offering • Business Wire • 05/13/2026 07:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/12/2026 04:15:05 AM
- CEL-SCI Corporation Announces Pricing of Public Offering • Business Wire • 05/12/2026 12:11:00 AM
- CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia • Business Wire • 05/11/2026 12:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/17/2026 09:07:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:03:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 10:59:38 AM
- CEL-SCI Reports Fiscal First Quarter 2026 Results • Business Wire • 02/18/2026 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 10:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 01:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 02:30:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 02:26:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 02:23:02 PM
- CEL-SCI Reports Fiscal 2025 Results • Business Wire • 12/29/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 01:48:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2025 10:00:37 PM
